Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms

Levis, Silvina

doi:10.1001/archinternmed.2011.330

Cited by 161 publications

(118 citation statements)

References 26 publications

(22 reference statements)

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…However, the outcomes of soy isoflavone treatment for the prevention of menopausal bone loss are conflicting. Although many researchers have shown that daily supplementation with soy isoflavones could prevent postmenopausal osteoporosis and improve bone strength, thus decreasing the risk of fracture in menopausal women (Wong et al, 2009;Taku et al, 2010Taku et al, , 2011, other studies have indicated that the daily administration of soy isoflavones could not prevent bone loss in menopausal women (Arjmandi et al, 2005;Levis et al, 2011). Equol is a metabolic end-product of soy isoflavones with high stability and a slow excretion speed.…”

Section: Discussionmentioning

confidence: 99%

Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor

Wang

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Phytoestrogens have been suggested as alternative treatment for postmenopausal osteoporosis. Equol, a metabolite of daidzein, has been shown to inhibit bone loss in ovariectomized mice and rats. However, whether or not equol influences the formation of bone has not yet been investigated. Therefore, we investigated the effect of equol on the proliferation and differentiation of rat primary osteoblasts and explored the involved mechanisms. Different equol concentrations significantly promoted the proliferation of osteoblasts after 48-and 72-h incubations. The alkaline phosphatase (ALP) activity also increased significantly in all of the equol and 17β-estradiol (E 2 ) groups, except for the lowest (0.01 µM) equol group. Equol also significantly elevated the osteocalcin levels. The effects of equol on osteoblast proliferation, ALP activity, and osteocalcin levels were blocked by the estrogen receptor (ER) antagonist ICI182780. After a 24-h incubation, the expression of protein kinase C alpha (PKCα) in osteoblasts was significantly increased by equol. In conclusion, our study demonstrated that equol could promote the proliferation and differentiation of rat osteoblasts through activating the ER-PKCα-related signaling pathway, suggesting that equol could promote bone formation. These results suggest that equol could be a potential alternative agent for the management of postmenopausal osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor

Wang

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…After 2 years, despite urine tests confirming that the women in the soy group had ingested nearly 20 times as much soy as those taking the placebo, there were no significant differences in bone density and no improvement regarding night sweats, insomnia, loss of libido, or vaginal dryness compared with the placebo group. There were few serious adverse effects in either group [42]. This study has been criticized for numerous study-design defects.…”

Section: Isoflavonoidsmentioning

confidence: 94%

Recent Developments in Pharmacotherapy for Vasomotor Symptoms

Utian

2012

Curr Obstet Gynecol Rep

View full text Add to dashboard Cite

Many women experience vasomotor symptoms (VMS) at or around the time of menopause. Hot flashes and night sweats are considered primary menopausal symptoms that may also be associated with sleep and mood disturbances, as well as decreased cognitive function. All of these symptoms may lead to social impairment and workrelated difficulties that significantly decrease overall quality of life. Hot flashes have shown a great deal of variability in their frequency and severity in women. In some women, hot flashes persist for several months, but in others, they may last for more than 10 years. Traditionally, VMS were reported to begin after menopause, but night sweats in particular most often begin in perimenopause, several years before the final period. The pathogenesis of hot flashes has not yet been fully elucidated. Hormonal therapy for menopauseassociated VMS has been the mainstay for the management of these symptoms for more than 50 years. However, because many women now want to avoid hormone therapy, there is a need for additional targeted therapies, validated by results from controlled clinical trials, that are safe, efficacious, cost-effective, and well tolerated by symptomatic menopausal women. The current status of these new pharmacotherapies for VMS is reviewed.

show abstract

“…One type of soybean known as black soybean, or seomoktae is traditionally used in Korea because its seed coat contains natural phenolic compounds (Zhao et al 2015). Seomoktae exerts protective effects against a number of disease such as cardiac diseases, metabolic syndromes, osteoporosis, and cancer (Levis et al 2011;Jung et al 2013). Seomoktae contains a high level of glutamine and asparagine residues, whose negatively charged carboxyl groups may bind calcium and, hense, may increase calcium bioavailability.…”

Section: Introductionmentioning

confidence: 99%

Physiological Activity of Coffee Beans and Roasted Black Beans (Rhynchosia nulubilis) Mixture Extracts for Coffee Alternative Beverage Development

Kim¹,

Lee²,

Ko³

et al. 2016

The Korean Journal of Food And Nutrition

View full text Add to dashboard Cite

This study was designed to develop and to qualify a coffee alternative beverage using a mixture of coffee beans and roasted black beans (Rhynchosia nulubilis). Therefore, the total isoflavone content (TIC), total phenol content (TPC), antioxidant activity, anti-inflammatory activity, NFATc1 (Nuclear factor of activated T-cells c1) expression in RANKL (receptor activator of nuclear factor kappa-B ligand)-stimulated RAW264.7 cells and sensory evaluation were measured for 5 different Cb (coffee bean)-RoS (roasted seomoktae) mixture extracts (Cb100RoS0, Cb75RoS25, Cb50RoS50, Cb25RoS75, and Cb0RoS100). Cb0RoS100 had the highest TIC (516.83±36.61 mg/100 g) and TPC (18.11±1.77 mg TAE/100 g) along with the highest antioxidant activity as measured by DPPH radical scavenging activity (73.55±8.11%) and ABTS radical scavenging activity (63.27±7.27%). Also, Cb0RoS100 showed the highest anti-inflammatory activity as measured by NO production (13.57±2.21 μM) and PGE2 production (3.25±0.21 ng/mL). The more the RoS ratio was increased in the mixtures of Cb-RoS, the more the NFATc1 protein expression was decreased in RANKL-stimulated RAW264.7 cells. In case of sensory evaluation, Cb50RoS50 had the highest scores for flavor, delicate flavor and overall quality, which were similar to those in Cb alone (Cb100RoS0). We suggest that the use of RoS replacement instead of Cb in/as a coffee alternative beverage may help to reduce the risk of caffeine-related bone loss and/or bone disease by effectively blocking NFATc1 expression in RANKLstimulated RAW264.7 cells compared with Cb alone.

show abstract

Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms

Abstract: clinicaltrials.gov Identifier: NCT00076050.

Cited by 161 publications

References 26 publications

Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor

Equol promotes rat osteoblast proliferation and differentiation through activating estrogen receptor

Recent Developments in Pharmacotherapy for Vasomotor Symptoms

Physiological Activity of Coffee Beans and Roasted Black Beans (Rhynchosia nulubilis) Mixture Extracts for Coffee Alternative Beverage Development

Contact Info

Product

Resources

About